C1q antibody

100% Secure


Sheep anti Human C1q:HRP

Product Type
Polyclonal Antibody
Isotype
Polyclonal IgG
Product Code Applications Pack Size List Price Quantity
2221-5004P
Datasheet
E
MSDS
1 ml

Sheep anti Human C1q antibody recognizes human C1q, a sub-component of complement C1. C1q associates with complement components C1r and C1s, which are required for the progression of the proteolytic complement cascade. Deficiency of C1q has been associated with lupus erythematosus and glomerulonephritis (Troedson et al. 2013).

Sheep anti human C1q antibody may cross react with C1q in other species.

Product Details

Target Species
Human
Product Form
Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
Antiserum Preparation
Antisera to human C1q were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG was prepared from whole serum by protein G affinity chromatography.
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
HRP stabiliser (BUF052A)
Immunogen
Human C1q.
Approx. Protein Concentrations
IgG concentration 1.0mg/ml

Storage Information

Storage
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee
12 months from date of despatch

More Information

UniProt
P02747
P02745
P02746
Entrez Gene
C1QA
C1QB
C1QC
GO Terms
GO:0005602 complement component C1 complex
GO:0006958 complement activation, classical pathway
GO:0007267 cell-cell signaling
GO:0045087 innate immune response
GO:0005576 extracellular region
GO:0030853 negative regulation of granulocyte differentiation
GO:0045650 negative regulation of macrophage differentiation
Regulatory
For research purposes only

Applications of C1q antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 1/100 1/400
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Useful Reagents Available

Description Product Code Applications Pack Size List Price Quantity
AbGUARD® HRP Stabilizer Plus BUF052A C E P WB 100 ml
AbGUARD® HRP Stabilizer Plus BUF052B C E P WB 500 ml
AbGUARD® HRP Stabilizer Plus BUF052C C E P WB 1000 ml
TMB Signal+ BUF054A E 100 ml
TMB Core BUF056A E 100 ml
TMB Core+ BUF062A E 100 ml

Application Based External Images

ELISA

Product Specific References

References for C1q antibody

  1. Nascimento, E.J. et al. (2009) Alternative complement pathway deregulation is correlated with dengue severity.
    PLoS One. 4:e6782
  2. Lewis, M.J. et al. (2007) The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.
    Mol Immunol. 45: 818-27.
  3. Jacobs, B.C. et al. (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
    Brain. 126: 2220-34.
  4. Arduin, E. et al. (2015) Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
    Mol Immunol. 63 (2): 456-63.
  5. Kao, D. et al. (2015) A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors.
    Cell Rep. 13 (11): 2376-85.
  6. Gearing, D.P. et al. (2016) In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
    J Vet Intern Med. 30 (4): 1129-37.